98%
921
2 minutes
20
An online solid phase extraction-ultra performance liquid chromatography-tandem mass spectrometry detection method was developed for the simultaneous determination of sacubitril and seven sartan drugs in blood serum in this study. The compounds were separated through a C column. Mass spectrometry of the samples was performed using a jet stream electrospray ion source (AJS, ESI+). The samples were detected via a multiple reaction monitoring (MRM) mode and quantified via a stable isotope internal standard method. 900 μL of prepared sample was injected and a run time of 12.5 minutes was obtained in this proposed method. The eight examined target compounds showed good linearity (r>0.994) in the corresponding mass concentration range and a lower limit of quantitation (LLOQ) was in the range of 0.05-0.1 μg/L. The recovery of the spiked serum samples ranged from 90.90 % to 106.20 % with relative standard deviations (RSDs) of 4.57 %-9.27 %. Five target compounds were detected in the actual serum samples using this method. The proposed method is simple to use, sensitive, accurate, and suitable for the trace detection of sacubitril and seven sartan drugs present in serum samples. The method can meet the needs for clinical monitoring of blood concentrations of this type of drug, while providing detection technology support for the development of compound preparations of sacubitril and other sartan drugs.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jpba.2024.116580 | DOI Listing |
PLoS One
September 2025
Department of Nephrology, Youyang Hospital, a Branch of The First Affiliated Hospital of Chongqing Medical University, China.
Background: Hypertension is associated with elevated mortality rates among individuals on maintenance hemodialysis (MHD). However, there is limited information regarding the efficacy and safety of sacubitril-valsartan (SV) in MHD patients suffering from hypertension. Consequently, this study aims to evaluate the efficacy and safety of SV in this specific patient population.
View Article and Find Full Text PDFMedicina (Kaunas)
August 2025
Division of Cardiology, Department of Medicine, Heart Vascular Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 06351, Republic of Korea.
: Optimal pharmacological treatment following left ventricular ejection fraction (LVEF) improvement remains largely unknown. This study compared the clinical outcomes of patients with heart failure (HF) with improved EF (HFimpEF) based on the maintenance of sacubitril/valsartan (S/V) or transition to a renin-angiotensin system blocker (RASB). : A total of 354 patients with recovered LVEF of at least 40% after S/V treatment from a single center were retrospectively analyzed.
View Article and Find Full Text PDFRen Fail
December 2025
Department of Pharmacy, Kochi Medical School Hospital, Kochi, Japan.
To evaluate the dose-dependent renoprotective effects of sacubitril/valsartan in heart failure patients. This retrospective observational study included patients with heart failure (Stage B or higher, B-type natriuretic peptide (BNP) >100 pg/mL or N-terminal proBNP >300 pg/mL) who initiated sacubitril/valsartan (SV) treatment. Patients were classified by final SV daily dose (50, 100, 200, or 400 mg) at 18 months.
View Article and Find Full Text PDFSci Rep
August 2025
Department of Rehabilitation Medicine, Jiangxi People's Hospital, Fenghe North Avenue 266, Nanchang, Jiangxi, China.
Chronic heart failure (CHF) affects 1-2% of adults in developed countries, with up to 50% experiencing sleep-disordered breathing (SDB). Sacubitril/valsartan (sac/val) has shown potential benefits on respiratory function, but its effect on SDB remains uncertain. This study aims to evaluates the effectiveness of sac/val on SDB and respiratory function in CHF patients.
View Article and Find Full Text PDFNat Commun
July 2025
National Heart Research Institute of Singapore, National Heart Centre Singapore, Singapore, Singapore.
Diffuse interstitial fibrosis is associated with adverse outcomes in hypertensive heart disease and may be reversible. Sacubitril/valsartan could offer greater anti-fibrotic effects than valsartan alone. In the REVERSE-LVH phase 2 open-labelled trial (clinicaltrials.
View Article and Find Full Text PDF